C
명문제약
017180KOSPI의약품 제조업43.0 / 100
Reference Date: 2026-04-13
Financial Score11.5 / 40
News Sentiment12.5 / 25
Momentum9.0 / 20
Disclosure10.0 / 15
AI Analysis: PBR is significantly undervalued vs. peers but the high debt ratio poses financial risk. Slightly down 2.5% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Myungmoon Pharmaceutical operates in two main segments: pharmaceutical/biotech and services. The company generates revenue through the production and distribution of key products such as cholesterol treatment medications. In 2025, consolidated sales reached approximately 195,247 million won, showing growth in both domestic and export markets.
Number of Employees
309people
Average Salary
63.1M KRW
Score Calculation Basis
Detailed Financial Score
PER
31.75Industry Average 14.800.0Point
2.1x industry avg (risky)
PBR
0.59Industry Average 1.045.5Point
Lower than industry avg (good)
ROE
1.37Industry Average 4.421.0Point
Well below industry avg
Debt Ratio
68.58Industry Average 11.980.0Point
5.7x industry avg (risky)
Trend 2023~20255.0 / 10 points
Revenue Growth Rate
2.0 / 3
Avg ▲7.3% (2-year basis)
Operating Profit Growth Rate
3.0 / 3
Avg ▲177.2% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -2.6% (improving, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position6.0Point
52w upper range (63%)
Current 1,810Won52-week high 1,94552-week low 1,571
1-month return2.0Point
1m -2.48% (slight drop)
Volume trend1.0Point
Volume decreasing
Detailed Disclosure
4 totalPositive 0Neutral 4Negative 0
- Neutral[기재정정]사업보고서 (2025.12)2026-03-30
- Neutral정기주주총회결과2026-03-26
- Neutral사업보고서 (2025.12)2026-03-18
- Neutral감사보고서제출2026-03-18